Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02911467 · ClinicalTrials.gov registry record · Phase 1
Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Rahul Aggarwal.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02911467: Clinical Trial Phase 1 study, sponsored by Rahul Aggarwal.
NCT02911467 is a Phase 1 study that was terminated before completion, run by Rahul Aggarwal. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02911467, a Phase 1 study, was terminated before completion, sponsored by Rahul Aggarwal.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging with Hyperpolarized Pyruvate (HP) (13C) as a predictive response biomarker to androgen signaling inhibition in patients with castration-resistant prostate cancer.
Primary Outcome
ASI-refractory disease is defined as progression by PCWG2 criteria within 6 months of treatment initiation. ASI-responsive disease includes all other tumors not meeting this criterion. A two sample t-test will be used to compare the mean intra-tumoral HP lac/pyr ratio between treatment-refractory versus treatment-responsive tumors. If a non-parametric distribution is observed, a Mann-Whitney test may also be used to compare the two groups.
Interventions
- DEVICE MRI
- DRUG Pyruvate (13C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-11-08 |
| Est. Completion | 2020-07-20 |
| Phase | Phase 1 |
Why NCT02911467 stopped before completion
NCT02911467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which MRI is the first listed.
NCT02911467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02911467 about?
NCT02911467 is a clinical study titled "Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer". This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging with Hyperpolarized Pyruvate (HP) (13C) as a predictive response biomarker to androgen signaling inhibition in patients with castration-resistant prostate cancer.
What is the current status of trial NCT02911467?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-11-08. Estimated completion is 2020-07-20.
What interventions are being tested in trial NCT02911467?
The interventions under investigation include: MRI (DEVICE), Pyruvate (13C) (DRUG).
Who is sponsoring clinical trial NCT02911467?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02911467's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI